Document is current
Any future updates will be listed below
-
Authors
Lee, Chih-Hung
Ou, Chien-Chih
Chen, Tim-Mo
- License Information
-
More Information
Article History
Received: 13 September 2024
Accepted: 5 November 2024
First Online: 25 November 2024
Declarations
:
: Chien-Chih Ou is the stockholder of OBIGEN PHARMA. Drs. Chih-Hung Lee and Tim-Mo Chen are the principal investigators for this phase I clinical trial and have no disclosures related to this product or the company.
: There were institutional approvals of experiments by the Tri-Service General Hospital and Kaohsiung Chang Gung Memorial Hospital Institutional Review Board. Written informed consent was obtained from all participants.
